Clinical trial
Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung…
NCT00072618 · Astellas Pharma Inc, Industry · Completed
Key facts
| NCT number | NCT00072618 |
|---|---|
| Title | Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients |
| Official title | A Phase I/II Multi-Center Study of Weekly Taxotere (Docetaxel) in Combination With Aptosyn (Exisulind) in Non-Small Cell Lung Cancer (NSCLC) Patients Who Have Failed a Prior Platinum-Containing Regimen |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Collaborators | OSI Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | NSCLC |
| Intervention type | Drug |
| Interventions | Exisulind |
| Enrollment | 52 |
| Start date | Oct 1, 2001 |
| Completion | Aug 1, 2003 |
| First posted | Nov 7, 2003 |
| Last update posted | Oct 20, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: